Latest Xoma Ltd (XOMA) Headlines
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Why XOMA Corp. Shares Slumped
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 2:09PM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
Downgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Tue Mar 11, 7:58AM CDT
XOMA (NASDAQ:XOMA) was downgraded from Buy to Hold at MLV & Co. today. The stock closed yesterday at $6.43 on volume of 3.6 million shares, above average daily volume of 2.6 million. There is potential upside of 55.5% for shares of XOMA based on a current price of $6.43 and an average consensus analyst price target of $10.00. The stock should hit resistance at its 50-day moving average (MA) of $7.69, as well as support at its 200-day MA of $5.36.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Down 30%, Worth a Look
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 06, 8:32PM CST
It's never a good sign when the first paragraph of a press release announcing clinical trial results for one disease starts talking about the other trials where the drug is being tested. Investors didn't buy the smokescreen XOMA put up on...
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
PR Newswire - Thu Mar 06, 11:22AM CST
Editor Note: For more information about this release, please scroll to bottom.
XOMA (XOMA) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 06, 8:48AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Hovnanian Enterprises, XOMA, and Yongye International Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 05, 7:31PM CST
Having seen a big drop on Monday and a big jump on Tuesday, stocks took the Goldilocks route Wednesday, as the broader market finished little changed as investors struggled to guess which direction macroeconomic and geopolitical issues will push the...
After Yesterday's Decline of 27.75%, XOMA Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 05, 5:20PM CST
XOMA (NASDAQ:XOMA) traded in a range yesterday that spanned from a low of $6.80 to a high of $7.53. Yesterday, the shares fell 27.8%, which took the trading range below the 3-day low of $8.06 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 05, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why XOMA Corp. Shares Zoomed Lower
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 12:57PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XOMA , a biopharmaceutical company...
Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:52AM CST
XOMA will not move gevokizumab into late-stage development for the EOA indication.
Why XOMA Corporation (XOMA) Is Plunging Today
at The Street - Wed Mar 05, 9:21AM CST
XOMA Corporation (XOMA) plunges after the biotechnology company announced that it would not move forward with late-stage testing of its drug gevokizumab as a treatment for a form of arthritis in the hand after results from two mid-stage studies did...
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Tue Mar 04, 3:57PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013.
XOMA Provides Update on Gevokizumab Proof-of-Concept Program
GlobeNewswire - Tue Mar 04, 3:37PM CST
-- Results from two Phase 2 erosive osteoarthritis of the hand studies do not support movement to pivotal development
Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:40PM CST
XOMA's gevokizumab already has orphan drug designation in the U.S. for three other indications.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Why XOMA Corp. Shares Slumped
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 2:09PM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
Downgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Tue Mar 11, 7:58AM CDT
XOMA (NASDAQ:XOMA) was downgraded from Buy to Hold at MLV & Co. today. The stock closed yesterday at $6.43 on volume of 3.6 million shares, above average daily volume of 2.6 million. There is potential upside of 55.5% for shares of XOMA based on a current price of $6.43 and an average consensus analyst price target of $10.00. The stock should hit resistance at its 50-day moving average (MA) of $7.69, as well as support at its 200-day MA of $5.36.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Down 30%, Worth a Look
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 06, 8:32PM CST
It's never a good sign when the first paragraph of a press release announcing clinical trial results for one disease starts talking about the other trials where the drug is being tested. Investors didn't buy the smokescreen XOMA put up on...
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
PR Newswire - Thu Mar 06, 11:22AM CST
Editor Note: For more information about this release, please scroll to bottom.
XOMA (XOMA) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 06, 8:48AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Hovnanian Enterprises, XOMA, and Yongye International Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 05, 7:31PM CST
Having seen a big drop on Monday and a big jump on Tuesday, stocks took the Goldilocks route Wednesday, as the broader market finished little changed as investors struggled to guess which direction macroeconomic and geopolitical issues will push the...
After Yesterday's Decline of 27.75%, XOMA Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 05, 5:20PM CST
XOMA (NASDAQ:XOMA) traded in a range yesterday that spanned from a low of $6.80 to a high of $7.53. Yesterday, the shares fell 27.8%, which took the trading range below the 3-day low of $8.06 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 05, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why XOMA Corp. Shares Zoomed Lower
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 12:57PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XOMA , a biopharmaceutical company...
Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:52AM CST
XOMA will not move gevokizumab into late-stage development for the EOA indication.
Why XOMA Corporation (XOMA) Is Plunging Today
at The Street - Wed Mar 05, 9:21AM CST
XOMA Corporation (XOMA) plunges after the biotechnology company announced that it would not move forward with late-stage testing of its drug gevokizumab as a treatment for a form of arthritis in the hand after results from two mid-stage studies did...
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Tue Mar 04, 3:57PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013.
XOMA Provides Update on Gevokizumab Proof-of-Concept Program
GlobeNewswire - Tue Mar 04, 3:37PM CST
-- Results from two Phase 2 erosive osteoarthritis of the hand studies do not support movement to pivotal development
Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:40PM CST
XOMA's gevokizumab already has orphan drug designation in the U.S. for three other indications.
